M Trovo1, N Giaj-Levra2,3, C Furlan1, M T Bortolin4, E Muraro5, J Polesel6, E Minatel1,4, R Tedeschi4, A R Filippi7, F Alongi8, U Ricardi7. 1. Department of Radiation Oncology, Centro di Riferimento Oncologico of Aviano, Aviano, Italy. 2. Radiation Oncology, Sacro Cuore Don Calabria Hospital, Via Don A. Sempreboni 5, Negrar, 37024, Verona, Italy. gmnicco@yahoo.it. 3. Department of Oncology, University of Torino, Turin, Italy. gmnicco@yahoo.it. 4. Department of Microbiology-Immunology and Virology, Centro di Riferimento Oncologico of Aviano, Aviano, Italy. 5. Department of Translational Research, Centro di Riferimento Oncologico of Aviano, Aviano, Italy. 6. Department of Epidemiology and Biostatistics, Centro di Riferimento Oncologico of Aviano, Aviano, Italy. 7. Department of Oncology, University of Torino, Turin, Italy. 8. Radiation Oncology, Sacro Cuore Don Calabria Hospital, Via Don A. Sempreboni 5, Negrar, 37024, Verona, Italy.
Abstract
PURPOSE: To assess kinetics of plasmatic cytokines during radiation therapy (RT) for locally advanced and early-stage non-small cell lung cancer (NSCLC). METHODS: This prospective study was conducted on 15 early-stage NSCLC underwent to extreme hypofractionated regimen (52 Gy in 8 fractions) with stereotactic body RT (SBRT), and 13 locally advanced NSCLC underwent to radical moderated hypofractionated regimen (60 Gy in 25 fractions) with intensity modulated RT (IMRT). For patients undergoing SBRT, peripheral blood samples were collected on the first day of SBRT (TFd), the last day (TLd) and 45 days (T45d) after the end of SBRT. For patients undergoing IMRT, blood samples were collected at: TFd, 2 weeks (T2w), 4 weeks (T4w), TLd, and T45d. The following cytokines were measured: IL-1, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17A, EGF, FGF-2, INF-γ, MIP-1α, MIP-1β, TGF-α, TNF-α, and VEGF. Cytokine levels measured in different RT time and compared. RESULTS: No difference in baseline levels of cytokines was documented between patient radiation approaches (except for MIP-1α). For SBRT patients, a mean reduction of IL-10 and IL-17 plasma level was documented between TLd and TFd, respectively (p < 0.05). For IMRT patients, a statistically significant (p < 0.05) mean plasma level reduction was documented between T4w and TFd for all the following cytokines: IL-1, IL-1ra, IL-2, IL-12, FGF-2, MIP-1α, MIP-1β, TGF-α, TNF-α, VEGF. CONCLUSIONS: SBRT and IMRT induce different plasmatic cytokine changes in NSCLC patients, supporting hypothesis that RT regimes of dose schedules and techniques have different impacts on the host immune response.
PURPOSE: To assess kinetics of plasmatic cytokines during radiation therapy (RT) for locally advanced and early-stage non-small cell lung cancer (NSCLC). METHODS: This prospective study was conducted on 15 early-stage NSCLC underwent to extreme hypofractionated regimen (52 Gy in 8 fractions) with stereotactic body RT (SBRT), and 13 locally advanced NSCLC underwent to radical moderated hypofractionated regimen (60 Gy in 25 fractions) with intensity modulated RT (IMRT). For patients undergoing SBRT, peripheral blood samples were collected on the first day of SBRT (TFd), the last day (TLd) and 45 days (T45d) after the end of SBRT. For patients undergoing IMRT, blood samples were collected at: TFd, 2 weeks (T2w), 4 weeks (T4w), TLd, and T45d. The following cytokines were measured: IL-1, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17A, EGF, FGF-2, INF-γ, MIP-1α, MIP-1β, TGF-α, TNF-α, and VEGF. Cytokine levels measured in different RT time and compared. RESULTS: No difference in baseline levels of cytokines was documented between patient radiation approaches (except for MIP-1α). For SBRT patients, a mean reduction of IL-10 and IL-17 plasma level was documented between TLd and TFd, respectively (p < 0.05). For IMRT patients, a statistically significant (p < 0.05) mean plasma level reduction was documented between T4w and TFd for all the following cytokines: IL-1, IL-1ra, IL-2, IL-12, FGF-2, MIP-1α, MIP-1β, TGF-α, TNF-α, VEGF. CONCLUSIONS: SBRT and IMRT induce different plasmatic cytokine changes in NSCLCpatients, supporting hypothesis that RT regimes of dose schedules and techniques have different impacts on the host immune response.
Authors: Walter J Curran; Rebecca Paulus; Corey J Langer; Ritsuko Komaki; Jin S Lee; Stephen Hauser; Benjamin Movsas; Todd Wasserman; Seth A Rosenthal; Elizabeth Gore; Mitchell Machtay; William Sause; James D Cox Journal: J Natl Cancer Inst Date: 2011-09-08 Impact factor: 13.506
Authors: Harm van Tinteren; Otto S Hoekstra; Egbert F Smit; Jan H A M van den Bergh; Ad J M Schreurs; Roland A L M Stallaert; Piet C M van Velthoven; Emile F I Comans; Fred W Diepenhorst; Paul Verboom; Johan C van Mourik; Pieter E Postmus; Maarten Boers; Gerrit J J Teule Journal: Lancet Date: 2002-04-20 Impact factor: 79.321
Authors: Marka Crittenden; Michael Gough; Kevin Harrington; Ken Olivier; Jill Thompson; Richard G Vile Journal: Cancer Res Date: 2003-09-01 Impact factor: 12.701
Authors: Marlies E Heuvers; Joachim G Aerts; Robin Cornelissen; Harry Groen; Henk C Hoogsteden; Joost P Hegmans Journal: BMC Cancer Date: 2012-12-05 Impact factor: 4.430
Authors: Heather M McGee; Megan E Daly; Sohelia Azghadi; Susan L Stewart; Leslie Oesterich; Jeffrey Schlom; Renee Donahue; Jonathan D Schoenfeld; Qian Chen; Shyam Rao; Ruben C Fragoso; Richard K Valicenti; Robert J Canter; Emmanual M Maverakis; William J Murphy; Karen Kelly; Arta M Monjazeb Journal: Int J Radiat Oncol Biol Phys Date: 2018-04-22 Impact factor: 7.038
Authors: Christopher A Barker; Samuel K Kim; Sadna Budhu; Konstantina Matsoukas; Anthony F Daniyan; Sandra P D'Angelo Journal: J Immunother Cancer Date: 2018-01-03 Impact factor: 13.751
Authors: Eric D Miller; James L Fisher; Karl E Haglund; John C Grecula; Meng Xu-Welliver; Erin M Bertino; Kai He; Peter G Shields; David P Carbone; Terence M Williams; Gregory A Otterson; Jose G Bazan Journal: Radiat Oncol Date: 2018-10-05 Impact factor: 3.481